Page last updated: 2024-12-08

erythromycin estolate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Erythromycin Estolate: A macrolide antibiotic, produced by Streptomyces erythreus. It is the lauryl sulfate salt of the propionic ester of erythromycin. This erythromycin salt acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID441371
CHEMBL ID2218877
CHEBI ID4846
SCHEMBL ID3331
MeSH IDM0007723

Synonyms (97)

Synonym
propionic acid, 2'-ester with erythromycin, dodecyl sulfate
(3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-4-(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-6-[3,4,6-trideoxy-3-(dimethylamino)-2-o-propanoyl-beta-d-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane
monopropionylerythromycin laurylsulfate
CHEBI:4846 ,
eritroger
lubomycine b
erythromycin, 2'-propionate, monododecyl sulfate (salt)
erythromycin, 2'-propanoate, dodecyl sulfate (salt)
erythromycin propionyl laurylsulfate
propionic acid, 2'-ester with erythromycin, dodecyl sulfate salt
nsc 263364
erythromycine estolate
einecs 222-532-4
ilosone
NCGC00180881-01
estolate, erythromycin
neo-erycinum
marcoeritrex
eriscel
lauryl sulfate propionyl erythromycin ester
propionylerythromycin lauryl sulfate
stellamicina
erythromycin propionate, compound with dodecyl sulfate
ery-toxinal dodecylsulfate
nsc-263364
roxomicina
estomicina
lauromicina
erytrarco
prospiocine
pels
erythromycin 2'-propionate dodecyl sulfate (salt)
erythromycin propionate lauryl sulfate
C08031
erythromycin estorate
erythromycin estolate
erythromycin estolate (usp)
erythromycin estorate (jan)
ilosone (tn)
D00851
SPECTRUM1501176
LMPK04000015
HMS2092J15
HMS500A11
HMS1921N13
dtxcid9017224
NCGC00255571-01
dtxsid1037224 ,
cas-3521-62-8
tox21_302229
pharmakon1600-01501176
nsc757880
nsc-757880
CCG-38968
xrj2p631hp ,
unii-xrj2p631hp
erythromycin estolate [usan:usp:ban:jan]
CHEMBL2218877
erythromycin lauryl sulfate, propionyl
propionyl erythromycin lauryl sulfate
erythromycin (as estolate)
AKOS015896121
erythromycin estolate [mi]
ilosone sulfa component erythromycin estolate
erythromycin estolate [who-dd]
erythromycin estolate [usp monograph]
erythromycin 2'-propionate dodecyl sulfate (salt).
erythromycin estolate [mart.]
erythromycin estolate [usan]
erythromycin estolate component of ilosone sulfa
erythromycin estolate [ep monograph]
erythromycin 2'-propionate dodecyl sulphate (salt).
erythromycin estolate [usp-rs]
erythromycin estolate [orange book]
erythromycin, 2'-propanoate, dodecyl sulphate (salt)
erythromycin estolate [vandf]
erythromycin estorate [jan]
S5532
bdbm31688
SCHEMBL3331
Q-201066
SR-05000002085-1
sr-05000002085
NCGC00180881-02
mfcd00084691
Q27106503
[(2s,3r,4s,6r)-4-(dimethylamino)-2-[[(3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] propanoat
D70256
HY-N7121
CS-0031228
(2s,3r,4s,6r)-4-(dimethylamino)-2-(((3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-14-ethyl-7,12,13-trihydroxy-4-(((2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)oxy)-3,5,7,9,11,13-hexamethyl-2,10-dioxooxacyclotetradecan-6-yl)oxy)-6-methyltet
erythromycin estolate (usp monograph)
erythromycin estolate (mart.)
erythromycin estolate (usp-rs)
(3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-4-(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-6-(3,4,6-trideoxy-3-(dimethylamino)-2-o-propanoyl-beta-d-xylo-hexopyranosyloxy)-3,5,7,9,11,13-hexamethyloxacyclotetradecane
erythromycin estolate (usan:usp:ban:jan)
erythromycin estolate (ep monograph)

Research Excerpts

Actions

ExcerptReferenceRelevance
"Erythromycin estolate in a lower dose administered only twice a day was equivalent to erythromycin ethylsuccinate in all aspects and proved to be adequate antimicrobial treatment for pertussis patients."( Comparison of erythromycin estolate and erythromycin ethylsuccinate for treatment of pertussis. The Erythromycin Study Group.
Hoppe, JE, 1992
)
1.37

Toxicity

ExcerptReferenceRelevance
" NT was less toxic than its parent compound, AT."( Protective effect of flavonoids on drug-induced hepatotoxicity in vitro.
Acosta, D; Davila, JC; Lenherr, A, 1989
)
0.28
" EF was not cytotoxic after 18 h incubation at concentrations up to 8 X 10(-4) M and EE was much more toxic than EB at all concentrations studied."( Erythromycin toxicity in primary cultures of rat hepatocytes.
Bégué, JM; Guillouzo, A; Villa, P,
)
0.13
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Other secondary outcomes were comparable, and the incidence of adverse events was not significantly different between the 2 groups."( Efficacy and Safety of Enteral Erythromycin Estolate in Combination With Intravenous Metoclopramide vs Intravenous Metoclopramide Monotherapy in Mechanically Ventilated Patients With Enteral Feeding Intolerance: A Randomized, Double-Blind, Controlled Pilo
Bhurayanontachai, R; Boonpeng, A; Charoensareerat, T; Lerkiatbundit, S; Navasakulpong, A; Pattharachayakul, S; Sitaruno, S, 2021
)
0.91

Pharmacokinetics

The lower percentage of hydrolysis of erythromycin estolate (41 versus 69%) combined with its longer half-life (5.5 years) led to a higher peak concentration of  erythroitin A. The maximum peak concentration was significantly greater than after administration of eriesmium phosphate.

ExcerptReferenceRelevance
" The lower percentage of hydrolysis of erythromycin estolate (41 versus 69%) combined with its longer half-life (5."( Pharmacokinetic advantages of erythromycin estolate over ethylsuccinate as determined by high-pressure liquid chromatography.
Bergeron, MG; Croteau, D; LeBel, M, 1988
)
0.83
" Maximum plasma peak concentrations, time to maximum concentrations, area under plasma concentration versus time curves, half-life of elimination, and mean residence times were determined from concentration versus time curves."( Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals.
Lakritz, J; Marsh, AE; Mihalyi, JE; Wilson, WD, 2000
)
0.63
"Maximum peak concentration of erythromycin A after administration of erythromycin phosphate was significantly greater than after administration of erythromycin estolate (2."( Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals.
Lakritz, J; Marsh, AE; Mihalyi, JE; Wilson, WD, 2000
)
0.83
"The purpose of this study was to describe and compare the pharmacokinetic properties of different formulations of erythromycin in dogs."( Pharmacokinetics of erythromycin after the administration of intravenous and various oral dosage forms to dogs.
Albarellos, GA; Ambros, LA; Hallu, RE; Kreil, VE; Montoya, L; Quaine, PC; Rebuelto, M; Tarragona, L; Waxman, S, 2008
)
0.35

Compound-Compound Interactions

This randomized, double-blind, controlled pilot study included 35 mechanically ventilated patients with feeding intolerance. Patients were randomly assigned to receive 10-mg metoclopramide intravenously every 6-8 hours in combination with 250-mg enteral erythromycin estolate.

ExcerptReferenceRelevance
"In this pilot study, we aimed to determine the efficacy and safety of enteral erythromycin estolate in combination with intravenous metoclopramide compared to intravenous metoclopramide monotherapy in mechanically ventilated patients with enteral feeding intolerance."( Efficacy and Safety of Enteral Erythromycin Estolate in Combination With Intravenous Metoclopramide vs Intravenous Metoclopramide Monotherapy in Mechanically Ventilated Patients With Enteral Feeding Intolerance: A Randomized, Double-Blind, Controlled Pilo
Bhurayanontachai, R; Boonpeng, A; Charoensareerat, T; Lerkiatbundit, S; Navasakulpong, A; Pattharachayakul, S; Sitaruno, S, 2021
)
1.14
"This randomized, double-blind, controlled pilot study included 35 mechanically ventilated patients with feeding intolerance who were randomly assigned to receive 10-mg metoclopramide intravenously every 6-8 hours in combination with 250-mg enteral erythromycin estolate (study group) or placebo every 6 hours for 7 days."( Efficacy and Safety of Enteral Erythromycin Estolate in Combination With Intravenous Metoclopramide vs Intravenous Metoclopramide Monotherapy in Mechanically Ventilated Patients With Enteral Feeding Intolerance: A Randomized, Double-Blind, Controlled Pilo
Bhurayanontachai, R; Boonpeng, A; Charoensareerat, T; Lerkiatbundit, S; Navasakulpong, A; Pattharachayakul, S; Sitaruno, S, 2021
)
1.09

Bioavailability

Relative bioavailability was determined after multiple-dose administration of erythromycin estolate. The results were compared to those from oral suspensions of ethylsuccinate.

ExcerptReferenceRelevance
" From these data it is apparent that intrapersonal variations in the absorption and disposition of erythromycin estolate are of a similar magnitude to interpersonal variations and should be borne in mind in the design and interpretation of comparative bioavailability studies involving similar formulations of this compound."( Variability in the absorption and disposition of erythromycin estolate in humans.
Kanfer, I; Stubbs, C, 1989
)
0.75
" Criteria for the evaluation of erythromycin bioavailability studies include study design, patient population, meal composition and timing, and assay methodology."( Selection of an oral erythromycin product.
Fraser, DG, 1980
)
0.26
"Relative bioavailability of erythromycin was determined after multiple-dose administration of erythromycin estolate in comparison to erythromycin ethylsuccinate both given as oral suspensions to twelve healthy volunteers."( [Comparison of the bioavailabilities of erythromycin estolate and erythromycin ethylsuccinate dry suspension preparations in steady state].
Blume, H; Elze, M; Potthast, H; Schug, B; Schwerdtle, R, 1995
)
0.78

Dosage Studied

The recommended dosage for either formulation (25 mg/kg, q 6 h) should be adequate for treatment of R equi infections in foals. The median bactericidal titers produced in plasma against Streptococcus pyogenes and Streptitis pneumoniae were significantly higher with erythromycin estolate than with the ethylsuccinate ester at both 2 and 8 h after dosing.

ExcerptRelevanceReference
"5 hr after dosing there is twice as much desmethyl-PE in plasma as PE."( Metabolism of propionyl erythromycin lauryl sulfate. I. Fate of the propionyl erythromycin moiety in the rat.
Marshall, FJ; McMahon, RE; Murphy, PJ; Williams, TL,
)
0.13
"The recommended dosage of erythromycin, without regard to the formulation prescribed, for children with streptococcal pharyngitis is 30 to 40 mg/kg/day."( Streptococcal pharyngitis therapy. A comparison of two erythromycin formulations.
Derrick, CW; Dillon, HC, 1979
)
0.26
" Absorption of all dosage forms, except the suspension, was delayed, and pharmacokinetic interpretation of both single- and multiple-dose data required incorporation of an absorption lag time."( Plasma levels following single and repeated doses of erythromycin estolate and erythromycin stearate.
Corrick-West, HP; Elliott, RL; Lyons, LL; Pitterle, ME; Welling, PG, 1979
)
0.51
"Streptococcal eradication rates of 86% were demonstrated in 97 patients seen on day 14 and in 73 patients seen on both days 14 and 28 after a ten-day course of erythromycin estolate therapy given at a dosage of 20 mg/kg/day, administered in two equal doses."( Erythromycin therapy for streptococcal pharyngitis.
Derrick, CW; Dillon, HC, 1976
)
0.45
"The effects of a new fluorinated macrolide (P-0501A) on drug metabolizing enzymes of rat liver were compared with three erythromycins--the base, the stearate and the estolate--after 7 days of dosing (1."( Effects of a new fluorinated macrolide (P-0501A) and other erythromycins on drug metabolizing enzymes in rat liver.
Bartosek, I; Casacci, F; Corti, F; De Marchi, F; Guaitani, A; Pacei, E; Villa, P, 1986
)
0.27
" For these reasons and based on results of the published clinical studies, the appropriate daily dosage for erythromycin estolate is 20 to 30 mg/kg/day and that for erythromycin ethylsuccinate is 40 mg/kg/day."( Erythromycin in the treatment of streptococcal infections.
Derrick, CW; Reilly, KM; Stallworth, JR,
)
0.34
" Each drug was dosed at 50 mg/kg/day and was given every 12 hours in two equally divided doses."( Cefadroxil monohydrate versus erythromycin in paediatric patients.
Trujillo, H, 1981
)
0.26
" The daily erythromycin dose of erythromycin ethylsuccinate was 50% higher than the respective dose of erythromycin estolate; the dosage interval tau was 12 h for erythromycin estolate and 8 h for erythromycin ethylsuccinate."( [Comparison of the bioavailabilities of erythromycin estolate and erythromycin ethylsuccinate dry suspension preparations in steady state].
Blume, H; Elze, M; Potthast, H; Schug, B; Schwerdtle, R, 1995
)
0.77
" Both drugs can be administered in a convenient twice-daily dosage schedule."( Multicenter, randomized, double-blind comparison of erythromycin estolate versus amoxicillin for the treatment of acute otitis media in children. AOM Study Group.
Noack, R; Scholz, H, 1998
)
0.55
"25 microg/ml (reported minimum inhibitory concentration for Rhodococcus equi) for at least 4 hours after intragastric administration of erythromycin phosphate or erythromycin estolate, suggesting that the recommended dosage for either formulation (25 mg/kg, q 6 h) should be adequate for treatment of R equi infections in foals."( Pharmacokinetics of erythromycin estolate and erythromycin phosphate after intragastric administration to healthy foals.
Lakritz, J; Marsh, AE; Mihalyi, JE; Wilson, WD, 2000
)
0.83
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
enzyme inhibitorA compound or agent that combines with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
aminoglycoside sulfate salt
erythromycin derivative
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (24)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency52.81040.007215.758889.3584AID1224835
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency36.42133.189029.884159.4836AID1224846
GLI family zinc finger 3Homo sapiens (human)Potency15.25150.000714.592883.7951AID1259369; AID1259392
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency45.45620.013326.981070.7614AID1346978
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency32.46050.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency40.51290.003041.611522,387.1992AID1159552
pregnane X nuclear receptorHomo sapiens (human)Potency9.06970.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency32.46050.000229.305416,493.5996AID743069
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency36.42130.001019.414170.9645AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency32.46050.023723.228263.5986AID743223
caspase-3Homo sapiens (human)Potency45.45620.013326.981070.7614AID1346978
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency36.10710.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency27.44370.001628.015177.1139AID1224843; AID1259385
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency36.421319.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency24.36460.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency74.91430.039147.5451146.8240AID1224845
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency36.81340.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency36.42130.042027.378961.6448AID743210; AID743228
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency36.26630.000627.21521,122.0200AID743202; AID743219
Cellular tumor antigen p53Homo sapiens (human)Potency45.45620.002319.595674.0614AID651631; AID720552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)11.40000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)10.03330.11007.190310.0000AID1209455; AID1443980; AID1443989
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)IC50 (µMol)3.09030.10472.71957.0795AID977603
Solute carrier organic anion transporter family member 1B3Homo sapiens (human)Ki2.35000.08002.46889.8000AID977604
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)IC50 (µMol)4.36520.05002.37979.7000AID977600
Solute carrier organic anion transporter family member 1B1Homo sapiens (human)Ki2.41000.04401.36305.0000AID977601
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (152)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
xenobiotic metabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
monoatomic ion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid and bile salt transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
heme catabolic processSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
transmembrane transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transportSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (46)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
serine-type endopeptidase inhibitor activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B3Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
bile acid transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
thyroid hormone transmembrane transporter activitySolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (32)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B3Homo sapiens (human)
plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basal plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
basolateral plasma membraneSolute carrier organic anion transporter family member 1B1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (38)

Assay IDTitleYearJournalArticle
AID977600pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977603pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID977601Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1443989Inhibition of recombinant human BSEP expressed in baculovirus infected sf9 cell plasma membrane vesicles assessed as reduction in ATP-dependent [3H]-taurocholate uptake in to vesicles preincubated for 10 mins followed by ATP addition measured after 10 to 2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID1443991Induction of mitochondrial dysfunction in Sprague-Dawley rat liver mitochondria assessed as inhibition of mitochondrial respiration per mg mitochondrial protein measured for 20 mins by A65N-1 oxygen probe based fluorescence assay2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID977604Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1443992Total Cmax in human administered as single dose2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1443995Hepatotoxicity in human assessed as drug-induced liver injury2014Hepatology (Baltimore, Md.), Sep, Volume: 60, Issue:3
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347158ZIKV-mCherry secondary qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347156DAPI mCherry counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347164384 well plate NINDS Rhodamine confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347163384 well plate NINDS AMC confirmatory qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (147)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990103 (70.07)18.7374
1990's15 (10.20)18.2507
2000's11 (7.48)29.6817
2010's14 (9.52)24.3611
2020's4 (2.72)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 45.15

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index45.15 (24.57)
Research Supply Index5.25 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index72.10 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (45.15)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials26 (15.85%)5.53%
Reviews11 (6.71%)6.00%
Case Studies14 (8.54%)4.05%
Observational0 (0.00%)0.25%
Other113 (68.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (72)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Methylnaltrexone vs Erythromycin for Facilitating Gastric Emptying Time in Critically Ill Patients Intolerant to Enteral Feeding [NCT01117376]Phase 242 participants (Anticipated)Interventional2010-05-31Terminated(stopped due to The study was prematurely terminated because of unavailibility of Methylnaltrexone in the region)
A Phase 1, Open-Label, Randomized, Cross-Over Study to Evaluate the Effects of Multiple Doses of Erythromycin on the Pharmacokinetics of a Single Dose of Pregabalin Controlled Release in Healthy Subjects [NCT01342198]Phase 118 participants (Actual)Interventional2011-06-30Completed
Investigating Anti-inflammatory Effects of Topical Antibiotics in an LPS Skin Challenge Model [NCT03779360]32 participants (Actual)Interventional2018-10-12Completed
To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis- A Randomized Placebo Controlled Study [NCT02528760]83 participants (Actual)Interventional2015-09-24Completed
Erythromycin Versus Neomycin Treatment for Overt Hepatic Encephalopathy: a Double-blind, Randomised, Controlled Trial. [NCT01097811]20 participants (Actual)Interventional2008-06-30Active, not recruiting
A Randomized, Placebo-controlled, Evaluator-blinded, Study to Assess the Anti-inflammatory Effects of Topical Erythromycin and Clindamycin in Patients With Inflammatory Facial Acne [NCT03883269]Phase 430 participants (Anticipated)Interventional2018-03-20Recruiting
Selections of Subjects With Dramatic Changes in Their Cardiac Repolarization Parameters After a Pharmacologic Stimulus Aiming to Collect Their Skin Biopsy and Blood Cells [NCT01338441]Phase 1130 participants (Anticipated)Interventional2011-03-31Completed
Treatment of Dowling Maera Type of Epidermolysis Bullosa Simplex by Oral Erythromycin [NCT01340235]Phase 38 participants (Anticipated)Interventional2011-06-30Recruiting
A Drug-drug Interaction Study of Ibrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-cell Malignancy [NCT02381080]Phase 126 participants (Actual)Interventional2015-05-19Completed
Assessing the Effectiveness of Integrative Treatment That Combines Interior and Exterior Treatment Plans in Pediatric Pneumonia: a Program by the Special Scientific Research Fund of Public Welfare Profession of China [NCT02362906]1,500 participants (Anticipated)Interventional2014-04-30Recruiting
Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutation in Familial Adenomatous Polyposis-protocol is Identical to Study No. 0519-10-TLV- Minors' Adjusted Version [NCT02354560]Phase 415 participants (Anticipated)Interventional2015-06-30Not yet recruiting
Pilot Study for Use of Prokinetics in Early Enteral Feeding of Preterm Infants ; Double Blind; Cross Over Study Comparing Eryththromycin, Metoclopramide and Placebo [NCT01569633]0 participants (Actual)Interventional2011-10-31Withdrawn(stopped due to very poor enrollment)
An Open-label, Parallel Group, Multiple-dose Investigation of the Pharmacokinetics of Tipranavir Soft Elastic Capsules SEDDS and Ritonavir Soft Gel Capsules and Their Effects on Cytochrome P-450 (3A4) Activity in Normal Healthy Volunteers [NCT02251132]Phase 1113 participants (Actual)Interventional2000-10-31Completed
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
Erythromycin as a Novel Therapy Against Familial Adenomatous Polyposis and Sporadic Colorectal Cancer by APC Nonsense Mutation Readthrough. [NCT02175914]Phase 420 participants (Anticipated)Interventional2014-06-30Recruiting
A Prospective, Multicenter Study on the Long-term Prognosis of Children With Bronchiectasis Treated With Low-dose Erythromycin [NCT03966066]70 participants (Anticipated)Interventional2019-08-31Not yet recruiting
An Open-Label Study to Estimate the Effect of Multiple Doses of Erythromycin on the Pharmacokinetics, Pharmacodynamics and Safety of a Single Dose of Rivaroxaban in Subjects With Renal Impairment and Normal Renal Function [NCT01309438]Phase 129 participants (Actual)Interventional2011-02-28Completed
A Phase 1, Single-center, Open-label, 2-part, 2-treatment Period, 1-sequence, Cross-over, Drug-drug Interaction Study to Investigate the Effect of Erythromycin on SAR443820 (Part A) and the Effect of Itraconazole on SAR443820 (Part B) in Healthy Adult Par [NCT05797753]Phase 116 participants (Actual)Interventional2022-02-18Completed
Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital [NCT02068170]178 participants (Actual)Observational2014-02-28Completed
A Phase 1, 3-Part, Open-label, Drug-Drug Interaction Study to Evaluate the Effect of a Moderate CYP3A4 Inhibitor, and of Strong and Moderate CYP3A4 Inducers on the Pharmacokinetics of TAK-279 in Healthy Subjects [NCT05995249]Phase 148 participants (Anticipated)Interventional2023-08-11Recruiting
An Open-label, Fixed-sequence Study in Healthy Study Participants to Evaluate the Effect of Coadministered Erythromycin on the Pharmacokinetics and Safety of Padsevonil [NCT03480243]Phase 128 participants (Actual)Interventional2018-03-27Completed
TREAT: Treatment of ppROM With Erythromycin vs. Azithromycin Trial [NCT03060473]Phase 3324 participants (Anticipated)Interventional2017-02-23Recruiting
ANTERO-4: A Clinical Investigation of the Effects of Erythromycin on Gastric Motility, Assessed With the VIPUN Gastric Monitoring System in Healthy Adults [NCT04066231]5 participants (Actual)Interventional2019-09-07Terminated(stopped due to Investigational medical device no longer available)
Immunomodulatory Role and Clinical Impact of Erythromycin in Critically Septic Patients: a Randomized Clinical Trial [NCT04665089]110 participants (Actual)Interventional2022-01-01Completed
The Efficacy and Safety Study of Medical Thoracoscope Cryotherapy Combined With Standard First-line Treatment of Advanced Non-small Cell Lung Cancer and Malignant Pleural Effusion: a Multicenter, Prospective, Randomized, Controlled Clinical Trial [NCT05291403]141 participants (Anticipated)Interventional2022-04-06Recruiting
A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and CYP3A Inhibitors, Erythromycin and Darunavir/Ritonavir (DRV/r) [NCT01323257]Phase 149 participants (Actual)Interventional2011-03-31Completed
Relationship Between Gastric Emptying and Glycemic Variability in Type 1 Diabetes Mellitus [NCT02755064]Phase 130 participants (Actual)Interventional2010-06-30Completed
An Open, Prospective, Randomized, Multi-Center Study of the Efficacy and Safety of Intravenous Followed by Oral Azithromycin vs. Cefuroxime Monotherapy or Plus Oral Erythromycin for the Treatment of Chinese Hospitalized Patients With Community- Acquired P [NCT00648726]Phase 3139 participants (Actual)Interventional2003-01-31Completed
The Role of Induced Phase 3 Contractions in the Control of Hunger and Food Intake [NCT02633579]28 participants (Actual)Interventional2012-10-31Completed
Randomized Phase III Trial of Cefazolin or Combination of Cefazolin and Erythromycin or Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of the Membranes [NCT01401179]Phase 3101 participants (Actual)Interventional2005-04-30Completed
Effect of Intravenous Bolus Infusion of Erythromycin Prior to Endoscopy in Patients Presenting With Variceal Bleeding: A Prospective, Randomized, Double- Blind ,Placebo Controlled, Trial [NCT01060267]102 participants (Actual)Interventional2007-01-31Completed
Transplacental Transfer of Drugs Used in Pregnant Women [NCT02622802]250 participants (Actual)Interventional2012-11-30Completed
[NCT00999232]Phase 40 participants Interventional2004-10-31Completed
A Randomized, Open Label Study to Compare the Use of the Dermatological Creams Verutex, Eritex and Fisiogel in the Management of Skin Rash Associated With Tarceva Treatment in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer. [NCT00718315]Phase 3201 participants (Actual)Interventional2009-04-30Completed
[NCT00000120]Phase 30 participants Interventional1985-01-31Completed
Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer [NCT00148070]Phase 245 participants (Actual)Interventional1999-03-31Completed
The Effect of Intravenous Erythromycin on Gastric Emptying in Patients Undergoing Rapid Sequence Intubation for Full Stomach - A Randomised, Placebo-controlled, Double-blind Study [NCT00827216]Phase 2132 participants (Actual)Interventional2009-01-31Completed
Pilot Study of a Multi-Drug Regimen for Severe Pulmonary Fibrosis in Hermansky-Pudlak Syndrome [NCT00467831]Phase 1/Phase 23 participants (Actual)Interventional2007-04-30Terminated(stopped due to insufficient enrollment)
Erythromycin Versus Amoxicillin for Treatment of Antenatal Chlamydia Trachomatis Infection: A Randomized Controlled Trial [NCT01946256]Phase 2220 participants (Actual)Interventional2013-10-31Completed
[NCT02212821]Phase 414 participants (Actual)Interventional2014-09-30Completed
Comparison of Two Macrolides, Azithromycin and Erythromycin, for Symptomatic Treatment of Gastroparesis [NCT01323582]Phase 226 participants (Actual)Interventional2009-02-28Terminated(stopped due to Original investigator left this institution, replacement investigator retired.)
Prevention of Colon Ischemia During Aortic Aneurysm (AAA) Repair [NCT00671203]Phase 3500 participants (Anticipated)Interventional2007-06-30Completed
Comparison of the Effect of Metoclopramide Versus Erythromycin on Gastric Residual Volume [NCT04682691]Early Phase 145 participants (Actual)Interventional2021-01-01Enrolling by invitation
A Comparative Study in the Clinical and Microbial Efficacy of Topical Besifloxocin Ophthalmic Suspension 0.6% With Erythromycin Ophthalmic Ointment 0.5% BID for the Management of Acute Blepharitis [NCT01478256]Phase 430 participants (Actual)Interventional2011-08-31Completed
Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer [NCT00146042]Phase 222 participants (Actual)Interventional1999-03-31Completed
Red Low Level LASER Versus Narrow Band Ultraviolet B in the Treatment of Facial Acne Vulgaris [NCT04254601]45 participants (Actual)Interventional2018-04-01Completed
Preterm Premature Rupture of Membranes: Erythromycin Versus Azithromycin a Randomized Trial Comparing Their Efficacy to Prolong Latency (PEACE Trial) [NCT01556334]Phase 30 participants (Actual)Interventional2010-04-30Withdrawn(stopped due to Terminated before starting due to need for IND determined by FDA.)
Phase III Trial of Antibiotics to Reduce Chorioamnionitis-Related Perinatal HIV Transmission [NCT00021671]Phase 33,720 participants InterventionalCompleted
Randomised Double Blind Placebo Controlled Trial of Effects of Long Term Low Dose Oral Erythromycin Therapy in Patients With Chronic Obstructive Pulmonary Disease [NCT00147667]Phase 2/Phase 3120 participants Interventional2004-04-30Active, not recruiting
Effects of Erythromycin on Binge Eating and GI Function in Bulimia Nervosa [NCT00304187]Phase 229 participants (Actual)Interventional2004-09-30Completed
In Urgency Hight Digestive Haemorrhage : Gastric Preparation for Endoscopy [NCT00259220]Phase 3270 participants (Actual)Interventional2005-12-31Completed
The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers [NCT00318201]Phase 47 participants (Actual)Interventional2006-04-30Completed
Effect of Erythromycin Before Endoscopy of Patients With Subtotal Gastrectomy (STG), High Risk of Gastric Stasis : Randomized and Prospective Study [NCT01659619]Phase 2114 participants (Actual)Interventional2012-04-30Completed
Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of Quality of Life in Patients With Ras-wildtype Colorectal Cancer [NCT01668498]Phase 288 participants (Actual)Interventional2011-05-31Completed
Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopic Examination in Patients With Upper Gastrointestinal Bleeding. A Prospective Randomized Trial. [NCT01716572]Phase 3122 participants (Anticipated)Interventional2012-02-29Active, not recruiting
Study of Erythromycin in GER-Associated Apnea of the Newborn [NCT01825473]40 participants (Anticipated)Interventional2012-09-30Recruiting
COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure [NCT02481219]122 participants (Actual)Interventional2015-05-31Completed
Low-Dose Long-Term Prescription of Erythromycin in Mustard-Induced Bronchiolitis Obliterans [NCT00367419]Phase 40 participants InterventionalCompleted
An Open-Label Study in HIV+ Patients to Determine the Effects of Nevirapine (Viramune) on the Pharmacokinetics of Clarithromycin and Activity of Cytochrome 3A4. [NCT00002194]Phase 136 participants InterventionalCompleted
A Phase 2/3, Randomized, Open-Label, Multi-center Study to Determine the Safety and Efficacy of Solithromycin in Adolescents and Children With Suspected or Confirmed Community-Acquired Bacterial Pneumonia [NCT02605122]Phase 2/Phase 397 participants (Actual)Interventional2016-04-30Terminated(stopped due to Development not proceeding)
A Phase 1, Randomised, Open Label, Two Sequence, Two Treatment, Two Way Crossover Study to Estimate the Steady-state Effect of Erythromycin on the Single Dose Pharmacokinetics of Ph-797804 in Healthy Subjects [NCT01589614]Phase 112 participants (Actual)Interventional2012-06-30Completed
A Two-Part, Open-Label, Fixed-Sequence, Two-Period Crossover Study to Assess the Effects of Erythromycin on the Pharmacokinetics of Relugolix, Estradiol, and Norethindrone After Administration of the Relugolix/Estradiol/Norethindrone Acetate Fixed-Dose Co [NCT04714554]Phase 143 participants (Actual)Interventional2021-01-06Completed
Randomized Control Trial Comparing Prokinetics and Their Influence on Endoscopy Outcomes for Upper GI Bleed. [NCT02017379]4 participants (Actual)Interventional2014-06-30Terminated(stopped due to Could not recruit any subjects)
[NCT00373919]0 participants InterventionalNot yet recruiting
[NCT00368342]Phase 40 participants InterventionalCompleted
Antibiotics and the Prolongation of Pregnancy in Preterm Labor With an Advanced Cervical Exam [NCT00589329]20 participants (Actual)Interventional2007-12-31Terminated(stopped due to published data suggest potential harm in other investigations.)
Comparative Study Between Different Methods of Enteral Feeding in Acute Severe Pancreatitis [NCT04406506]60 participants (Actual)Observational [Patient Registry]2018-06-10Completed
Influence of Erythromycin on ad Libitum Food Intake and the Evaluation of Motilin in Food Timing in Healthy Volunteers and Patients [NCT03024879]Phase 415 participants (Anticipated)Interventional2014-03-31Enrolling by invitation
Magnetic Resonance (MR) Evaluation of the Effect of Erythromycin Upon Gastric and Small Bowel Motility [NCT01379183]Phase 2/Phase 340 participants (Actual)Interventional2011-06-30Completed
Establishment a Nucleic Acid Rapid Detection Technology Platform for Detecting Pathogenic Bordetella and Its Drug Resistance Genes [NCT04535505]0 participants (Actual)Observational2022-07-31Withdrawn(stopped due to Not as a lead unit)
Effects of a Physiotherapy Program in Patients Hospitalized Due to Pneumonia [NCT02515565]60 participants (Anticipated)Interventional2015-09-30Recruiting
Erythromycin in Parkinson's Disease: A Pilot Study of Its Effects on Levodopa Pharmacokinetics and Pharmacodynamics [NCT02005029]18 participants (Actual)Interventional2013-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00304187 (2) [back to overview]Binge Frequency
NCT00304187 (2) [back to overview]Percent of Meal Remaining/Minute
NCT00467831 (1) [back to overview]Survival at 2 Years
NCT00589329 (2) [back to overview]Respiratory Distress
NCT00589329 (2) [back to overview]Length of Pregnancy Prolongation
NCT00718315 (9) [back to overview]Percentage of Participants With Pruritus
NCT00718315 (9) [back to overview]Time to Appearance of Skin Rash
NCT00718315 (9) [back to overview]Percentage of Participants With Erythema Stratified by Severity Grade
NCT00718315 (9) [back to overview]Percentage of Participants With Pain Stratified by Severity Grade
NCT00718315 (9) [back to overview]Percentage of Participants With Pruritus Stratified by Severity Grade
NCT00718315 (9) [back to overview]Percentage of Participants With Skin Rash Stratified by Severity Grade
NCT00718315 (9) [back to overview]Percentage of Participants With Pain
NCT00718315 (9) [back to overview]Percentage of Participants Who Develop Skin Rash
NCT00718315 (9) [back to overview]Percentage of Participants With Erythema
NCT01323582 (8) [back to overview]Change in Time to 50% Emptying: Post Test Less Baseline Pooled Over Orderings
NCT01323582 (8) [back to overview]Change in Time to 50% Gastric Emptying: Post Test Less Baseline Pooled Over Orderings
NCT01323582 (8) [back to overview]TLAG (Time From Ingestion of Meal to Start of Gastric Emptying)
NCT01323582 (8) [back to overview]Time in Minutes for 50% of the Ingested Meal to Empty the Stomach With a Standardized Breath Test: Half the of the Week 11 Value (Period 2) Less Half the of the Week 4 Value (Period 1). This Estimates the Effect Size.
NCT01323582 (8) [back to overview]NDI Score
NCT01323582 (8) [back to overview]Gastroparesis Cardinal Symptom Index (GCSI) Score Change From Baseline to Post Treatment
NCT01323582 (8) [back to overview]Gastroparesis Cardinal Symptom Index (GCSI) Score
NCT01323582 (8) [back to overview]Does GCSI Score Improve (Lower) on Treatment, Pooling the AZ Patients Over Their Treatment Periods? Endpoint is Difference in Post-test Less Baseline
NCT01379183 (6) [back to overview]Small Intestine Volume
NCT01379183 (6) [back to overview]Small Intestine and Colon Volume
NCT01379183 (6) [back to overview]Jejunal Volume
NCT01379183 (6) [back to overview]Ileal Volume
NCT01379183 (6) [back to overview]Gastric Volume
NCT01379183 (6) [back to overview]Colonic Volume
NCT01478256 (2) [back to overview]Improvement in Signs and Symptoms of Blepharitis
NCT01478256 (2) [back to overview]Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics
NCT02005029 (11) [back to overview]Area Under the Curve 0-4 Hours for Plasma Levodopa After Erythromycin Versus Placebo
NCT02005029 (11) [back to overview]Change in Dyskinesia
NCT02005029 (11) [back to overview]Comfortable 20 Feet Gait Speed (CGS)
NCT02005029 (11) [back to overview]Five Times Sit-to-stand Test
NCT02005029 (11) [back to overview]Gastric Emptying Time
NCT02005029 (11) [back to overview]Mean Cmax of Plasma Levodopa After Erythromycin Versus Placebo
NCT02005029 (11) [back to overview]Timed up and go Test (TUAG) Comfortable Speed
NCT02005029 (11) [back to overview]Timed up and go Test (TUAG) Fast Speed
NCT02005029 (11) [back to overview]MDS-UPDRS Part 3 (Movement Disorders Society- Unified Parkinson's Disease Rating Scale)
NCT02005029 (11) [back to overview]9-hole Peg Test Right Hand
NCT02005029 (11) [back to overview]9-hole Peg Test Left Hand
NCT02481219 (6) [back to overview]Colonic Transit Time of Two Different Bowel Preparation Methods for PillCam CCE
NCT02481219 (6) [back to overview]Comparing of Completion Rate of Capsule of Two Different Bowel Preparation Methods for PillCam CCE
NCT02481219 (6) [back to overview]Excretion Rate of Capsule Within 12 Hours of Two Different Bowel Preparation Methods for PillCam CCE
NCT02481219 (6) [back to overview]Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE)
NCT02481219 (6) [back to overview]Comparing Polyp Detection Rate of Two Different Bowel Preparation Methods for PillCam CCE
NCT02481219 (6) [back to overview]Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE
NCT02605122 (4) [back to overview]Summary of Clinical Cure
NCT02605122 (4) [back to overview]Summary of Clinical Improvement
NCT02605122 (4) [back to overview]Summary of Early Clinical Response
NCT02605122 (4) [back to overview]Overview of Adverse Events By Treatment Arm
NCT03480243 (28) [back to overview]Apparent Elimination Rate Constant (Lambdaz) of Padsevonil for Multiple Doses in Plasma
NCT03480243 (28) [back to overview]Apparent Terminal Elimination Half-life at Steady-state (t1/2,ss) of Padsevonil for Multiple Doses in Plasma
NCT03480243 (28) [back to overview]Apparent Total Clearance at Steady-state (CL/Fss) of Padsevonil for Multiple Doses in Plasma
NCT03480243 (28) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours (AUC(0-12)) of Padsevonil for Single Dose
NCT03480243 (28) [back to overview]Area Under the Plasma Concentration-time Curve Over a Dosing Interval (12 Hours) (AUCtau) of Padsevonil for Multiple Doses
NCT03480243 (28) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Padsevonil for Single Dose
NCT03480243 (28) [back to overview]Maximum Observed Steady-state Plasma Concentration (Cmax, ss) of Padsevonil for Multiple Doses
NCT03480243 (28) [back to overview]Minimum Observed Plasma Concentration (Cmin) of Padsevonil for Single Dose
NCT03480243 (28) [back to overview]Percentage of Participants Experiencing Treatment-Emergent Non-serious Adverse Events (AEs) During the Study
NCT03480243 (28) [back to overview]Formation Clearance (CLform) of Padsevonil Metabolites (1, 2, and 3) in the Urine for Multiple Doses
NCT03480243 (28) [back to overview]Cumulative Amount (Ae) of Padsevonil and Metabolites (1, 2, and 3) Excreted Into the Urine for Single Dose
NCT03480243 (28) [back to overview]Cumulative Amount (Ae) of Padsevonil and Metabolites (1, 2, and 3) Excreted Into the Urine for Multiple Doses
NCT03480243 (28) [back to overview]Area Under the Plasma Concentration-time Curve Over a Dosing Interval (12 Hours) (AUCtau) of Padsevonil Metabolites (1 and 2) for Multiple Doses
NCT03480243 (28) [back to overview]Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours (AUC(0-12)) of Padsevonil Metabolites (1 and 2) for Single Dose
NCT03480243 (28) [back to overview]Time of Maximum Plasma Concentration (Tmax) of Padsevonil for Single Dose
NCT03480243 (28) [back to overview]Time of Maximum Plasma Concentration (Tmax) of Padsevonil for Multiple Doses
NCT03480243 (28) [back to overview]Predose Observed Plasma Concentration (Ctrough) of Padsevonil for Multiple Doses
NCT03480243 (28) [back to overview]Renal Clearance (CLr) of Padsevonil and Metabolites (1 and 2) for Single Dose in Urine
NCT03480243 (28) [back to overview]Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) During the Study
NCT03480243 (28) [back to overview]Renal Clearance (CLr) of Padsevonil and Metabolites (1 and 2) for Multiple Doses in Urine
NCT03480243 (28) [back to overview]Metabolite-to-parent Ratio for Cmax of Padsevonil Metabolites (1 and 2) in Plasma
NCT03480243 (28) [back to overview]Metabolite-to-parent Ratio for AUCtau of Padsevonil Metabolites (1 and 2) in Plasma
NCT03480243 (28) [back to overview]Metabolite-to-parent Ratio for AUC(0-12) of Padsevonil Metabolites (1 and 2) in Plasma
NCT03480243 (28) [back to overview]Maximum Observed Steady-state Plasma Concentration (Cmax, ss) of Padsevonil Metabolites (1 and 2) for Multiple Doses
NCT03480243 (28) [back to overview]Maximum Observed Plasma Concentration (Cmax) of Padsevonil Metabolites (1 and 2) for Single Dose
NCT03480243 (28) [back to overview]Fraction (fe) of Padsevonil and Metabolites (1, 2, and 3) Excreted Into the Urine for Single Dose
NCT03480243 (28) [back to overview]Fraction (fe) of Padsevonil and Metabolites (1, 2, and 3) Excreted Into the Urine for Multiple Doses
NCT03480243 (28) [back to overview]Formation Clearance (CLform) of Padsevonil Metabolites (1, 2, and 3) in the Urine for Single Dose

Binge Frequency

Binge frequency was assessed by patient diary. All patients were asked to keep a diary of the number of daily binge eating and vomiting episodes which was collected at each weekly visit. (NCT00304187)
Timeframe: Measured at Week 7

InterventionBinge Episodes/Week (Mean)
Erythromycin10.4
Placebo11.3

[back to top]

Percent of Meal Remaining/Minute

percent of meal remaining/minute (NCT00304187)
Timeframe: Measured at Week 7

Interventionpercent of meal remaining/minute (Mean)
Erythromycin-.339
Placebo-.177

[back to top]

Survival at 2 Years

The number of subjects surviving after 24 months on study. (NCT00467831)
Timeframe: 24 months

Interventionparticipants (Number)
Multi-Drug Regimen0

[back to top]

Respiratory Distress

Respiratory distress will be defined by the clinical record documentation of the neonatal team. (NCT00589329)
Timeframe: newborn nursery

InterventionParticipants (Count of Participants)
Group A2
Group B1

[back to top]

Length of Pregnancy Prolongation

The length of time (in hours) from initiation of therapy to delivery will establish the latency (NCT00589329)
Timeframe: Measured from randomization to delivery in hours

Interventionhours (Mean)
Group A4
Group B4

[back to top]

Percentage of Participants With Pruritus

Pruritus is defined as intense localized itching (NCT00718315)
Timeframe: Days 0, 15, and 30

Interventionpercentage of participants (Number)
Fisiogel36.1
Stiemicyn47.6
Verutex29.5

[back to top]

Time to Appearance of Skin Rash

Time to occurence of skin rash was calculated as the number of days from Day 0 until the first appearance of skin rash as defined by NCI-CTCAE (NCT00718315)
Timeframe: Days 0, 15, and 30

InterventionDays (Median)
Fisiogel16.0
Stiemicyn15.0
Verutex15.0

[back to top]

Percentage of Participants With Erythema Stratified by Severity Grade

The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist. (NCT00718315)
Timeframe: 30 Days

,,
Interventionpercentage of participants (Number)
Grade 0Grade 1Grade 2Grade 3Grade 4Grade 5
Fisiogel37.739.323.0000
Stiemicyn39.736.522.21.600
Verutex52.539.36.61.600

[back to top]

Percentage of Participants With Pain Stratified by Severity Grade

The severity of pain was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist. (NCT00718315)
Timeframe: 30 Days

,,
Interventionpercentage of participants (Number)
Grade 0Grade 1Grade 2Grade 3Grade 4Grade 5
Fisiogel82.011.54.91.600
Stiemicyn73.022.24.8000
Verutex85.26.66.61.600

[back to top]

Percentage of Participants With Pruritus Stratified by Severity Grade

The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death; Severity graded by oncologist. (NCT00718315)
Timeframe: 30 Days

,,
Interventionpercentage of participants (Number)
Grade 0Grade 1Grade 2Grade 3Grade 4Grade 5
Fisiogel63.919.714.81.600
Stiemicyn52.431.714.31.600
Verutex70.524.63.31.600

[back to top]

Percentage of Participants With Skin Rash Stratified by Severity Grade

The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death (NCT00718315)
Timeframe: 30 Days

,,
Interventionpercentage of participants (Number)
Grade 0Grade 1Grade 2Grade 3Grade 4Grade 5
Fisiogel29.821.149.1000
Stiemicyn25.018.356.7000
Verutex18.343.335.03.300

[back to top]

Percentage of Participants With Pain

Pain is defined as an unpleasant feeling often caused by intense or damaging stimuli (NCT00718315)
Timeframe: Days 0, 15, and 30

Interventionpercentage of participants (Number)
Fisiogel16.4
Stiemicyn25.4
Verutex13.4

[back to top]

Percentage of Participants Who Develop Skin Rash

"Skin rash was assessed by the investigator and dermatologists (the latter ones only through pictures) and scored according to (National cancer Institute -Common Terminology Criteria for Adverse Events ) NCI-CTCAE ( version 3 (line Rash/desquamation - short name rash)." (NCT00718315)
Timeframe: 30 Days

Interventionpercentage of participants (Number)
Fisiogel60.0
Stiemicyn69.2
Verutex73.1

[back to top]

Percentage of Participants With Erythema

Erythema is defined as redness of the skin or mucous membranes, caused by hyperemia of superficial capillaries (NCT00718315)
Timeframe: Days 0, 15, and 30

Interventionpercentage of participants (Number)
Fisiogel56.7
Stiemicyn56.7
Verutex43.3

[back to top]

Change in Time to 50% Emptying: Post Test Less Baseline Pooled Over Orderings

Patients will be given a standardized meal enriched with a labeled material and the breath samples are then collected and analyzed. The estimated time to reaching 50% of the accumulated contents is recorded. (NCT01323582)
Timeframe: at baseline before initiation of the treatment and after completion of each treatment period.

Interventionminutes (Mean)
Azithromycin-15.0

[back to top]

Change in Time to 50% Gastric Emptying: Post Test Less Baseline Pooled Over Orderings

Patients will be given a standardized meal enriched with a labeled material and the breath samples are then collected and analyzed. The estimated time to reaching 50% of the accumulated contents is recorded. (NCT01323582)
Timeframe: Baseline and end of treatment period

InterventionMinutes (Mean)
Erythromycin-11.8

[back to top]

TLAG (Time From Ingestion of Meal to Start of Gastric Emptying)

This is defined as the time from ingestion of the meal to the beginning of the emptying process in minutes. Because the difference is RX-B -RX A in one group and RX A -RX B in the other, the difference between these two estimates twice the effect size. Hence the Half is applied, as is standard in the two sample method for crossover studies. (NCT01323582)
Timeframe: Weeks 4 and 11 (end of periods)

InterventionMinutes (Mean)
Erythromycin First Then Azithromycin-1.71
Azithromycin Then Erythromycin-0.22

[back to top]

Time in Minutes for 50% of the Ingested Meal to Empty the Stomach With a Standardized Breath Test: Half the of the Week 11 Value (Period 2) Less Half the of the Week 4 Value (Period 1). This Estimates the Effect Size.

Patients will be given a standardized meal enriched with a labeled material and the breath samples are then collected and analyzed. The estimated time to empty 50% (t 1/2) of the accumulated contents is recorded. Because the difference is RX-B -RX A in one group and RX A -RX B in the other, the difference between these two estimates twice the effect size. Hence the Half is applied, as is standard in the two sample method for crossover studies. (NCT01323582)
Timeframe: Weeks 4 and 11 (end of periods)

InterventionMinutes (Mean)
Erythromycin First Then Azithromycin-1.6
Azithromycin Then Erythromycin-5.2

[back to top]

NDI Score

"Nepean Dyspepsia Index (NDI) is a measure of symptom status and quality of life in functional dyspepsia. This scale is scored using each subscale (Tension, interference with daily activities), Eating/drinking, Knowledge/control, work/study) and adding up the items for each of the five subscale score (2-10). Total score range would be 10-50).~For the NDI, a lower number is better meaning the symptom is not effecting quality of life and a higher score closer to 50 is worse meaning it is effecting patients quality of life.~Reference: Talley NJ, Verlinden M, Jones M. Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and developement of a new 10-iten short form. Aliment Pharmacol Ther 2001: 15: 207-216.~Because the difference is RX-B -RX A in one group and RX A -RX B in the other, the difference between these two estimates twice the effect size. Hence the Half is applied, as is standard in the two sample method for crossover studies." (NCT01323582)
Timeframe: Weeks 4 and 11 (end of periods)

Interventionunits on a scale (Median)
Erythromycin First Then Azithromycin1.65
Azithromycin Then Erythromycin1.30

[back to top]

Gastroparesis Cardinal Symptom Index (GCSI) Score Change From Baseline to Post Treatment

"This is a Validated instrument for measuring symptom severity in patients with gastroparesis. This scoring is based on a Likert Scale from (0-5) with zero being no symptom and five being very severe symptoms on 9 subscales, making the overall score range from 0-45. The higher the score, the more severe patient's symptoms are. The scale is reported in the references. The change was calculated by measuring the end of treatment minus baseline GCSI score.~Negative value reflects this change." (NCT01323582)
Timeframe: Baseline and end of treatment period

Interventionunits on a scale (Mean)
Erythromycin-5.32

[back to top]

Gastroparesis Cardinal Symptom Index (GCSI) Score

"This is a Validated instrument for measuring symptom severity in patients with gastroparesis. This scoring is based on a Likert Scale from (0-5) with zero being no symptoms and five being very severe symptoms on 9 subscales, making the overall score range from 0-45. The higher the score, the more severe patient's symptoms.~Reference for GCSI: Revicki DA, REntz AM, Dubois D, et al. Development and validation of a patient-assessed gastroparesis symptoms severity measure: the Gastroparesis Cardinal Symptom Index. Ailment Pharm Ther 2003; 18: 141:50.~Because the difference is RX-B -RX A in one group and RX A -RX B in the other, the difference between these two estimates twice the effect size. Hence the Half is applied, as is standard in the two sample method for crossover studies." (NCT01323582)
Timeframe: Weeks 4 and 11 (end of periods)

Interventionunits on a scale (Mean)
Erythromycin First Then Azithromycin-1.6
Azithromycin Then Erythromycin-2.9

[back to top]

Does GCSI Score Improve (Lower) on Treatment, Pooling the AZ Patients Over Their Treatment Periods? Endpoint is Difference in Post-test Less Baseline

"This is a Validated instrument for measuring symptom severity in patients with gastroparesis. This scoring is based on a Likert Scale from (0-5) with zero being no symptom and five being very severe symptoms on 9 subscales, making the overall score range from 0-45. The higher the score, the more severe patient's symptoms are. The scale is reported in the references.~This is a calculation taken with GCSI score at end of treatment minus baseline. Negative value reflects this change." (NCT01323582)
Timeframe: Baseline and end of treatment period

Interventionunits on a scale (Median)
Azithromycin-6.40

[back to top]

Small Intestine Volume

A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath. (NCT01379183)
Timeframe: Approximately 60 minutes after beginning ingestion of fluid volume

InterventionmL (Mean)
Erythromycin698
Placebo607

[back to top]

Small Intestine and Colon Volume

A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath. (NCT01379183)
Timeframe: Approximately 60 minutes after beginning ingestion of fluid volume

InterventionmL (Mean)
Erythromycin910
Placebo781

[back to top]

Jejunal Volume

The jejunum is the section of the small intestine between the duodenum and the ileum. A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath. (NCT01379183)
Timeframe: Approximately 60 minutes after beginning ingestion of fluid volume

InterventionmL (Mean)
Erythromycin450
Placebo359

[back to top]

Ileal Volume

The Ileal is the terminal portion of the small intestine extending from the jejunum to the cecum. A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath. (NCT01379183)
Timeframe: Approximately 60 minutes after beginning ingestion of fluid volume

InterventionmL (Mean)
Erythromycin248
Placebo248

[back to top]

Gastric Volume

A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. MR images of the abdomen were acquired with a torso phased array coil and a 1.5 tesla magnet MRI. Gastric volumes were assessed with an axial 3D axial gradient echo sequence, which imaged the entire stomach in 13 seconds. (NCT01379183)
Timeframe: Approximately 60 minutes after beginning ingestion of fluid volume

InterventionmL (Mean)
Erythromycin262
Placebo718

[back to top]

Colonic Volume

A Magnetic Resonance (MR) enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel. Small bowel volumes were evaluated with 5 mm thick coronal slices using a fat-suppressed true fast imaging with steady state precession sequence while the participant held his or her breath. (NCT01379183)
Timeframe: Approximately 60 minutes after beginning ingestion of fluid volume

InterventionmL (Mean)
Erythromycin190
Placebo180

[back to top]

Improvement in Signs and Symptoms of Blepharitis

Signs and symptoms of blepharitis were scored and determined before and after treatment with two different antibiotics (NCT01478256)
Timeframe: Four weeks

Interventionparticipants (Number)
Besifloxocin15
Erythromycin15

[back to top]

Evaluate Improvement of Bacterial Cultures With Two Different Topical Antibiotics

Compare improvement of microbial cultures (greater inhibition of bacterial growth) with the two antibiotics used to treat blepharitis (NCT01478256)
Timeframe: Three weeks

Interventionparticipants (Number)
Besifloxocin15
Erythromycin15

[back to top]

Area Under the Curve 0-4 Hours for Plasma Levodopa After Erythromycin Versus Placebo

Mean Area under the Curve 0-4 hours for plasma levodopa after erythromycin versus placebo. Plasma samples were collected at the following times post-levodopa dose: 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 240 minutes. (NCT02005029)
Timeframe: 2 weeks, between visits 2 and 3

Interventionng/mL*min (Mean)
Erythromycin123237
Placebo103584

[back to top]

Change in Dyskinesia

Mean total AIMS (Abnormal Involuntary Movements Scale) score after receiving erythromycin minus mean total AIMS score after receiving placebo. The AIMS test has a total of twelve items rating involuntary movements of various areas of the patient's body. Ten of the items are rated on a five-point scale of severity from 0-4. The scale is rated from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe). Two of the items are not scored. Total score range is from 0 to 40. Higher scores represent more severe dyskinesia (a worse outcome). (NCT02005029)
Timeframe: 2 weeks, between visits 2 and 3

Interventionunits on a scale (Mean)
Erythromycin0.875
Placebo0.375

[back to top]

Comfortable 20 Feet Gait Speed (CGS)

Change in motor function as assessed by comfortable 20 feet gait speed (CGS) (NCT02005029)
Timeframe: 2 weeks, between visits 2 and 3

Interventionseconds (Mean)
Erythromycin4.26
Placebo4.10

[back to top]

Five Times Sit-to-stand Test

Change in motor function as measured by Five times sit-to-stand test. This test measures the total time to complete 5 repetitions of sit to stand. (NCT02005029)
Timeframe: 2 weeks, between visits 2 and 3

Interventionseconds (Mean)
Erythromycin11.09
Placebo10.09

[back to top]

Gastric Emptying Time

Mean gastric emptying time in minutes as measured by SmartPill (NCT02005029)
Timeframe: 2 weeks, between visits 2 and 3

Interventionminutes (Mean)
Erythromycin105
Placebo180

[back to top]

Mean Cmax of Plasma Levodopa After Erythromycin Versus Placebo

Mean Cmax of plasma levodopa after erythromycin versus placebo. Plasma samples were collected at the following times post-levodopa dose: 15, 30, 45, 60, 75, 90, 105, 120, 150, 180, 210, and 240 minutes. (NCT02005029)
Timeframe: 2 weeks, between visits 2 and 3

Interventionng/mL (Mean)
Erythromycin1267
Placebo1395

[back to top]

Timed up and go Test (TUAG) Comfortable Speed

Change in motor function as assessed by timed up and go test (comfortable speed). This test measures the total time to stand from a chair, walk 10 feet, and return to sitting. (NCT02005029)
Timeframe: 2 weeks, between visits 2 and 3

Interventionseconds (Mean)
Erythromycin8.67
Placebo8.26

[back to top]

Timed up and go Test (TUAG) Fast Speed

Change in motor function as assessed by timed up and go test (fast speed). This test measures the total time to stand from a chair, walk 10 feet, and return to sitting. (NCT02005029)
Timeframe: 2 weeks, between visits 2 and 3

Interventionseconds (Mean)
Erythromycin6.79
Placebo6.85

[back to top]

MDS-UPDRS Part 3 (Movement Disorders Society- Unified Parkinson's Disease Rating Scale)

Part 3 of this scale is a standardized physical assessment that quantifies the total burden of motor symptoms in Parkinson's disease patients. Each of the 18 items on the scale is rated from 0 (none, 1 (slight), 2 (mild), 3 (moderate) and 4 (severe). Scores range from 0-72. Higher scores represent a more severe burden of motor symptoms (a worse outcome). (NCT02005029)
Timeframe: 2 weeks, between visits 2 and 3

,
Interventionunits on a scale (Mean)
"Before or off levodopa""After or on levodopa"
Erythromycin30.7517.13
Placebo25.3716.50

[back to top]

9-hole Peg Test Right Hand

Change in motor function as assessed by 9-hole peg test for upper extremity manipulation/dexterity. This test measures the total time required to place and remove 9 holes in a pegboard. Each hand is tested separately. (NCT02005029)
Timeframe: 2 weeks, between visits 2 and 3

Interventionseconds (Mean)
Erythromycin25.36
Placebo25.80

[back to top]

9-hole Peg Test Left Hand

Change in motor function as assessed by 9-hole peg test for upper extremity manipulation/dexterity. This test measures the total time required to place and remove 9 holes in a pegboard. Each hand is tested separately. (NCT02005029)
Timeframe: 2 weeks, between visits 2 and 3

Interventionseconds (Mean)
Erythromycin29.36
Placebo27.33

[back to top]

Colonic Transit Time of Two Different Bowel Preparation Methods for PillCam CCE

Colonic transit time of two different bowel preparation was assessed from RAPID video in total and by segment (NCT02481219)
Timeframe: an expected average of 3 weeks from study procedure

Interventionhours (Median)
Bowel Preparation Regimen - Control2.8
Bowel Preparation Regimen-Test2.4

[back to top]

Comparing of Completion Rate of Capsule of Two Different Bowel Preparation Methods for PillCam CCE

Will be assessed from RAPID video in total and by segment (NCT02481219)
Timeframe: an expected average of 3 weeks from study procedure

Interventionpercentage of participants (Number)
Bowel Preparation Regimen -Control76.9
Bowel Preparation Regimen-Test90.9

[back to top]

Excretion Rate of Capsule Within 12 Hours of Two Different Bowel Preparation Methods for PillCam CCE

Will be assesses by applicable case report form (CRF) (NCT02481219)
Timeframe: an expected average of 3 weeks from study procedure

Interventionpercentage of participants (Number)
Bowel Preparation Regimen -Control80.4
Bowel Preparation Regimen-Test90.9

[back to top]

Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE)

The primary endpoint is the bowel cleansing level, as determined by a standardized 4-point grading scale, assessed in total and by segment (cecum, ascending, transverse, descending/sigmoid, and rectum). (NCT02481219)
Timeframe: Within two weeks of study procedure

,
Interventionpercentage of particpants (Number)
Overall Excellent cleansingCecum Excellent cleansingAscending Excellent cleansingTransverse Excellent cleansingDescending Excellent cleansingRectum Excellent cleansingOverall Good cleansingCecum Good cleansingAscending Good cleansingTransverse Good cleansingDescending Good cleansingRectum Good cleansingOverall Fair cleansingCecum Fair cleansingAscending Fair cleansingTransverse Fair cleansingDescending Fair cleansingRectum Fair cleansingOverall Poor cleansingCecum Poor cleansingAscending Poor cleansingTransverse Poor cleansingDescending Poor cleansingRectum Poor cleansing
Bowel Preparation Regimen -Control6.814.012.210.69.5070.554.063.361.773.856.122.730.022.527.716.746.502.02.0002.4
Bowel Preparation Regimen-Test16.714.618.214.618.510.059.352.760.060.063.052.024.130.921.825.518.536.001.80002.0

[back to top]

Comparing Polyp Detection Rate of Two Different Bowel Preparation Methods for PillCam CCE

Will be assessed from RAPID video in total and by segment (NCT02481219)
Timeframe: an expected average of 3 weeks from study procedure

,
Interventionpercentage of participants (Number)
Overall (any size)Cecum (any size)Ascending (any size)Transverse (any size)Descending (any size)rectum (any size)Overall (polyps ≥6mm)Cecum (polyps ≥6mm)Ascending (polyps ≥6mm)Transverse (polyps ≥6mm)Descending (polyps ≥6mm)Rectum (polyps ≥6mm)Overall (polyps ≥10mm)Cecum Overall (polyps ≥10mm)Ascending Overall (polyps ≥10mm)Transverse (polyps ≥10mm)Descending (polyps ≥10mm)Rectum (polyps ≥10mm)
Bowel Preparation Regimen -Control46.86.014.04.331.924.421.32.02.04.312.87.38.502.004.34.9
Bowel Preparation Regimen-Test58.214.69.17.329.132.036.412.73.67.316.46.014.67.33.61.83.62.0

[back to top]

Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE

Will be assesses by applicable CRF (NCT02481219)
Timeframe: Adverse Events (AE) were collected starting from the screening visit and until 5-9 days following the PillCam procedure day.

Interventionpercentage of participants with >1 AE (Number)
Bowel Preparation Regimen -Control3.4
Bowel Preparation Regimen-Test19.4

[back to top]

Summary of Clinical Cure

Clinical cure was assessed using the latest efficacy evaluation conducted on Day 16 (+/- 4 days) post-randomization, and was defined as resolution of all presenting signs/symptoms of CABP (excluding cough), no development of new signs/symptoms of CABP, and no requirement for an additional antibiotic. (NCT02605122)
Timeframe: Short-term follow-up at 16 days (+/- 4 days)

Interventionpercentage of participants (Number)
Solithromycin60.0
Standard of Care68.4

[back to top]

Summary of Clinical Improvement

Clinical improvement was assessed using the latest efficacy evaluation conducted on last day of treatment (+48 hours), and was defined identically to the early clinical response. (NCT02605122)
Timeframe: Last day of Treatment (+48 hours)

Interventionpercentage of participants (Number)
Solithromycin64.5
Standard of Care81

[back to top]

Summary of Early Clinical Response

Early clinical response (ECR) was defined using the latest efficacy evaluation from Day 2 (if subject discharged prior to Day 2), Day3, or Day 4, and was defined as improvement in at least 1 presenting sign/symptom of CABP with no deterioration in any signs/symptoms of CABP and no requirement for an additional antibiotic. (NCT02605122)
Timeframe: During Treatment Days 3 to 4

Interventionpercentage of participants (Number)
Solithromycin66.7
Standard of Care46.7

[back to top]

Overview of Adverse Events By Treatment Arm

Summary of subjects experiencing Treatment Emergent Adverse Events (TEAE) through Day 16 visit and Treatment Emergent Serious Adverse Events (TESAE) through Day 28 visit (28 days +/- 4 days after randomization) (NCT02605122)
Timeframe: Up to 28 days post-treatment

,
InterventionParticipants (Count of Participants)
TEAETESAE
Solithromycin241
Standard of Care71

[back to top]

Apparent Elimination Rate Constant (Lambdaz) of Padsevonil for Multiple Doses in Plasma

lambdaz: The apparent elimination rate constant of padsevonil for multiple doses in plasma. Lambdaz was expressed in liters per hour (l/hour). (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 72 hours post last dose of Padsevonil (PSL) (Treatment Period 1 and 2); from pre-dose to 120 hours post last dose of PSL (Treatment Period 3)

Interventionlhour (Geometric Mean)
Padsevonil (Period 1) (PK-PPS)0.1049
Padsevonil (Period 2) (PK-PPS)0.1006
Padsevonil and Erythromycin (Period 3b) (PK-PPS)0.07975

[back to top]

Apparent Terminal Elimination Half-life at Steady-state (t1/2,ss) of Padsevonil for Multiple Doses in Plasma

t½,ss: The apparent terminal elimination half-life at steady-state of padsevonil for multiple doses in plasma. t1/2, ss was expressed in hours (h). (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 72 hours post last dose of Padsevonil (PSL) (Treatment Period 1 and 2); from pre-dose to 120 hours post last dose of PSL (Treatment Period 3)

Interventionhours (Median)
Padsevonil (Period 1) (PK-PPS)6.465
Padsevonil (Period 2) (PK-PPS)6.649
Padsevonil and Erythromycin (Period 3b) (PK-PPS)8.548

[back to top]

Apparent Total Clearance at Steady-state (CL/Fss) of Padsevonil for Multiple Doses in Plasma

CL/Fss: The apparent total clearance at steady-state of padsevonil for multiple doses in plasma. CL/Fss was expressed in milliliters per hour (mL/hour). (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 72 hours post last dose of Padsevonil (PSL) (Treatment Period 1 and 2); from pre-dose to 120 hours post last dose of PSL (Treatment Period 3)

InterventionmL/hour (Geometric Mean)
Padsevonil (Period 1) (PK-PPS)48810
Padsevonil (Period 2) (PK-PPS)43970
Padsevonil and Erythromycin (Period 3b) (PK-PPS)19710

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours (AUC(0-12)) of Padsevonil for Single Dose

AUC(0-12): The area under the plasma concentration-time curve from time zero to 12 hours of padsevonil for single dose . AUC(0-12) was expressed in hours times nanograms per milliliter (hours*ng/mL). (NCT03480243)
Timeframe: Predose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose on Day 1, 12, and 26

Interventionhours*ng/mL (Geometric Mean)
Padsevonil (Period 1) (PK-PPS)1428
Padsevonil (Period 2) (PK-PPS)1571
Padsevonil and Erythromycin (Period 3b) (PK-PPS)2576

[back to top]

Area Under the Plasma Concentration-time Curve Over a Dosing Interval (12 Hours) (AUCtau) of Padsevonil for Multiple Doses

AUCtau: The area under the plasma concentration-time curve over a dosing interval (12 hours) of padsevonil for multiple doses. AUC(tau) was expressed in hours times nanograms per millilitre (hours*ng/mL). (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 72 hours post last dose of Padsevonil (PSL) (Treatment Period 1 and 2); from pre-dose to 120 hours post last dose of PSL (Treatment Period 3)

Interventionhours*ng/mL (Geometric Mean)
Padsevonil (Period 1) (PK-PPS)2049
Padsevonil (Period 2) (PK-PPS)2274
Padsevonil and Erythromycin (Period 3b) (PK-PPS)5073

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Padsevonil for Single Dose

Cmax: The maximum observed plasma concentration of padsevonil for single dose . Cmax was expressed in nanograms per milliliter (ng/mL). (NCT03480243)
Timeframe: Predose and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, and 12 hours postdose on Day 1, 12, and 26

Interventionng/mL (Geometric Mean)
Padsevonil (Period 1) (PK-PPS)366.6
Padsevonil (Period 2) (PK-PPS)385.3
Padsevonil and Erythromycin (Period 3b) (PK-PPS)697.4

[back to top]

Maximum Observed Steady-state Plasma Concentration (Cmax, ss) of Padsevonil for Multiple Doses

Cmax, ss: The maximum observed steady-state plasma concentration of padsevonil for multiple doses. Cmax, ss was expressed in nanograms per millilitre (ng/mL). (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 72 hours post last dose of Padsevonil (PSL) (Treatment Period 1 and 2); from pre-dose to 120 hours post last dose of PSL (Treatment Period 3)

Interventionng/mL (Geometric Mean)
Padsevonil (Period 1) (PK-PPS)475.0
Padsevonil (Period 2) (PK-PPS)473.9
Padsevonil and Erythromycin (Period 3b) (PK-PPS)1010

[back to top]

Minimum Observed Plasma Concentration (Cmin) of Padsevonil for Single Dose

Cmin: The minimum observed plasma concentration of padsevonil for single dose. Cmin was expressed in nanograms per millilitre (ng/mL). (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 12 hours post first dose of Padsevonil for each Treatment Period

Interventionng/mL (Geometric Mean)
Padsevonil (Period 1) (PK-PPS)2.857
Padsevonil (Period 2) (PK-PPS)5.643
Padsevonil and Erythromycin (Period 3b) (PK-PPS)4.286

[back to top]

Percentage of Participants Experiencing Treatment-Emergent Non-serious Adverse Events (AEs) During the Study

Treatment-emergent Adverse Events (TEAEs) were defined as those events which started on or after the date of first dose of UP0057 IMP, or events in which severity worsened on or after the date of first dose of UP0057 study medication. (NCT03480243)
Timeframe: From beginning of the first Treatment Period (Day 1) to the Safety Follow-up Visit (up to 48 days )

Interventionpercentage of participants (Number)
Padsevonil (Period 1+2) (FAS)100
Erythromycin (Period 3a) (FAS)11.1
Padsevonil and Erythromycin (Period 3b) (FAS)96.3
Erythromycin (Period 3c) (FAS)19.2

[back to top]

Formation Clearance (CLform) of Padsevonil Metabolites (1, 2, and 3) in the Urine for Multiple Doses

CLform: The formation clearance of padsevonil metabolites (1, 2, and 3) in the urine for multiple doses. CLform was expressed in milliliters per hour (mL/hour). (NCT03480243)
Timeframe: Urine samples were taken 0 to 12 hours, 12 to 24 hours,and 24 to 48 hours post last PSL dose during Treatment Period 1 and 2; 0 to 12 hours, 12 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours post last dose of PSL during Treatment Period 3

,,
InterventionmL/h (Geometric Mean)
Metabolite 1Metabolite 2Metabolite 3
Padsevonil (Period 1) (PK-PPS)295.3733125150
Padsevonil (Period 2) (PK-PPS)294.6662220890
Padsevonil and Erythromycin (Period 3b) (PK-PPS)166.4259311170

[back to top]

Cumulative Amount (Ae) of Padsevonil and Metabolites (1, 2, and 3) Excreted Into the Urine for Single Dose

Ae: The cumulative amount of padsevonil and its metabolites (1, 2, and 3) excreted into the urine for single dose. Ae was expressed in milligrams (mg). (NCT03480243)
Timeframe: Urine samples were taken 0 to 12 hours post first dose of Padsevonil during each Treatment Period

,,
Interventionmilligrams (Geometric Mean)
PadsevonilMetabolite 1Metabolite 2Metabolite 3
Padsevonil (Period 1) (PK-PPS)0.039140.210110.5329.11
Padsevonil (Period 2) (PK-PPS)0.040540.23339.42327.44
Padsevonil and Erythromycin (Period 3b) (PK-PPS)0.049870.23099.76426.09

[back to top]

Cumulative Amount (Ae) of Padsevonil and Metabolites (1, 2, and 3) Excreted Into the Urine for Multiple Doses

Ae: The cumulative amount of padsevonil and its metabolites (1, 2, and 3) excreted into the urine for multiple doses. Ae was expressed in milligrams (mg). (NCT03480243)
Timeframe: Urine samples were taken 0 to 12 hours, 12 to 24 hours,and 24 to 48 hours post last PSL dose during Treatment Period 1 and 2; 0 to 12 hours, 12 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours post last dose of PSL during Treatment Period 3

,,
Interventionmilligrams (Geometric Mean)
PadsevonilMetabolite 1Metabolite 2Metabolite 3
Padsevonil (Period 1) (PK-PPS)0.058250.618815.0370.83
Padsevonil (Period 2) (PK-PPS)0.057410.665715.0765.30
Padsevonil and Erythromycin (Period 3b) (PK-PPS)0.12740.879713.6781.36

[back to top]

Area Under the Plasma Concentration-time Curve Over a Dosing Interval (12 Hours) (AUCtau) of Padsevonil Metabolites (1 and 2) for Multiple Doses

AUCtau: The area under the plasma concentration-time curve over a dosing interval (12 hours) of padsevonil metabolites (1 and 2) for multiple doses. AUCtau was expressed in hours times nanograms per milliliter (hours*ng/mL). (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 72 hours post last dose of Padsevonil (PSL) (Treatment Period 1 and 2); from pre-dose to 120 hours post last dose of PSL (Treatment Period 3)

,,
Interventionhours*ng/mL (Geometric Mean)
Metabolite 1Metabolite 2
Padsevonil (Period 1) (PK-PPS)1748775.1
Padsevonil (Period 2) (PK-PPS)1993813.1
Padsevonil and Erythromycin (Period 3b) (PK-PPS)2625799.0

[back to top]

Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours (AUC(0-12)) of Padsevonil Metabolites (1 and 2) for Single Dose

AUC(0-12): The area under the plasma concentration-time curve from time zero to 12 hours of padsevonil metabolites (1 and 2) for single dose. AUC(0-12) was expressed in hours times nanograms per milliliter (hours*ng/mL). (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 12 hours post first dose of Padsevonil for each Treatment Period

,,
Interventionhours*ng/mL (Geometric Mean)
Metabolite 1Metabolite 2
Padsevonil (Period 1) (PK-PPS)828.3596.5
Padsevonil (Period 2) (PK-PPS)824.3534.4
Padsevonil and Erythromycin (Period 3b) (PK-PPS)905.6599.5

[back to top]

Time of Maximum Plasma Concentration (Tmax) of Padsevonil for Single Dose

Tmax: The time of maximum plasma concentration of padsevonil for single dose. Tmax was expressed in hours (h). (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 12 hours post first dose of Padsevonil for each Treatment Period

Interventionhours (Median)
Padsevonil (Period 1) (PK-PPS)3.000
Padsevonil (Period 2) (PK-PPS)1.500
Padsevonil and Erythromycin (Period 3b) (PK-PPS)1.500

[back to top]

Time of Maximum Plasma Concentration (Tmax) of Padsevonil for Multiple Doses

Tmax: The time of maximum plasma concentration of padsevonil for multiple doses. Tmax was expressed in hours (h). (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 72 hours post last dose of Padsevonil (PSL) (Treatment Period 1 and 2); from pre-dose to 120 hours post last dose of PSL (Treatment Period 3)

Interventionhours (Median)
Padsevonil (Period 1) (PK-PPS)1.750
Padsevonil (Period 2) (PK-PPS)1.500
Padsevonil and Erythromycin (Period 3b) (PK-PPS)2.000

[back to top]

Predose Observed Plasma Concentration (Ctrough) of Padsevonil for Multiple Doses

Ctrough: The predose observed plasma concentration of padsevonil for multiple doses. Ctrough was expressed in nanograms per millilitre (ng/mL). (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 72 hours post last dose of Padsevonil (PSL) (Treatment Period 1 and 2); from pre-dose to 120 hours post last dose of PSL (Treatment Period 3)

Interventionng/mL (Geometric Mean)
Padsevonil (Period 1) (PK-PPS)57.03
Padsevonil (Period 2) (PK-PPS)68.57
Padsevonil and Erythromycin (Period 3b) (PK-PPS)182.6

[back to top]

Renal Clearance (CLr) of Padsevonil and Metabolites (1 and 2) for Single Dose in Urine

CLr: The renal clearance of padsevonil and its metabolites (1 and 2) for single dose in urine. CLr was expressed in milliliters per hour (mL/hour). (NCT03480243)
Timeframe: Urine samples were taken 0 to 12 hours post first dose of Padsevonil during each Treatment Period

,,
InterventionmL/hour (Geometric Mean)
PadsevonilMetabolite 1Metabolite 2
Padsevonil (Period 1) (PK-PPS)27.40253.717640
Padsevonil (Period 2) (PK-PPS)25.80283.017630
Padsevonil and Erythromycin (Period 3b) (PK-PPS)19.36255.016290

[back to top]

Percentage of Participants Experiencing Treatment-Emergent Serious Adverse Events (SAEs) During the Study

"An SAE is any untoward medical occurrence that at any dose:~Results in death~Is life-threatening~Requires in patient hospitalization or prolongation of existing hospitalization~Is a congenital anomaly or birth defect~Is an infection that requires treatment parenteral antibiotics~Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above." (NCT03480243)
Timeframe: From beginning of the first Treatment Period (Day 1) to the Safety Follow-up Visit (up to 48 days )

Interventionpercentage of participants (Number)
Padsevonil (Period 1+2) (FAS)0
Erythromycin (Period 3a) (FAS)0
Padsevonil and Erythromycin (Period 3b) (FAS)0
Erythromycin (Period 3c) (FAS)0

[back to top]

Renal Clearance (CLr) of Padsevonil and Metabolites (1 and 2) for Multiple Doses in Urine

CLr: The renal clearance of padsevonil and its metabolites (1 and 2) for multiple doses in urine. CLr was expressed in milliliters per hour (mL/hour). (NCT03480243)
Timeframe: Urine samples were taken 0 to 12 hours, 12 to 24 hours,and 24 to 48 hours post last PSL dose during Treatment Period 1 and 2; 0 to 12 hours, 12 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours post last dose of PSL during Treatment Period 3

,,
InterventionmL/hours (Geometric Mean)
PadsevonilMetabolite 1Metabolite 2
Padsevonil (Period 1) (PK-PPS)28.43335.019390
Padsevonil (Period 2) (PK-PPS)25.24325.418530
Padsevonil and Erythromycin (Period 3b) (PK-PPS)25.12311.416470

[back to top]

Metabolite-to-parent Ratio for Cmax of Padsevonil Metabolites (1 and 2) in Plasma

Metabolite-to-parent ratio calculated as: Cmax of padsevonil metabolites (1 and 2) divided by Cmax of padsevonil following a single dose in plasma. Metabolite-to-parent ratio for Cmax was expressed as ratio. (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 12 hours post dose of Padsevonil for each Treatment Period

,,
Interventionratio (Geometric Mean)
Metabolite 1Metabolite 2
Padsevonil (Period 1) (PK-PPS)0.45440.3015
Padsevonil (Period 2) (PK-PPS)0.41190.2452
Padsevonil and Erythromycin (Period 3b) (PK-PPS)0.27170.1552

[back to top]

Metabolite-to-parent Ratio for AUCtau of Padsevonil Metabolites (1 and 2) in Plasma

Metabolite-to-parent ratio calculated as: AUCtau of padsevonil metabolites (1 and 2) divided by AUCtau of padsevonil following multiple dosing in plasma. Metabolite-to-parent ratio for AUCtau was expressed as ratio. (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 72 hours post last dose of Padsevonil (PSL) (Treatment Period 1 and 2); from pre-dose to 120 hours post last dose of PSL (Treatment Period 3)

,,
Interventionratio (Geometric Mean)
Metabolite 1Metabolite 2
Padsevonil (Period 1) (PK-PPS)0.85330.3783
Padsevonil (Period 2) (PK-PPS)0.87660.3576
Padsevonil and Erythromycin (Period 3b) (PK-PPS)0.51740.1575

[back to top]

Metabolite-to-parent Ratio for AUC(0-12) of Padsevonil Metabolites (1 and 2) in Plasma

Metabolite-to-parent ratio calculated as: AUC(0-12)of padsevonil metabolites (1 and 2) divided by AUC(0-12) of padsevonil following a single dose in plasma. Metabolite-to-parent ratio for AUC(0-12) was expressed as ratio. (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 12 hours post first dose of Padsevonil for each Treatment Period

,,
Interventionratio (Geometric Mean)
Metabolite 1Metabolite 2
Padsevonil (Period 1) (PK-PPS)0.57990.4176
Padsevonil (Period 2) (PK-PPS)0.52460.3401
Padsevonil and Erythromycin (Period 3b) (PK-PPS)0.35150.2327

[back to top]

Maximum Observed Steady-state Plasma Concentration (Cmax, ss) of Padsevonil Metabolites (1 and 2) for Multiple Doses

Cmax, ss: The maximum observed steady-state plasma concentration of padsevonil metabolites (1 and 2) for multiple doses. Cmax, ss was expressed in nanograms per millilitre (ng/mL). (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 72 hours post last dose of Padsevonil (PSL) (Treatment Period 1 and 2); from pre-dose to 120 hours post last dose of PSL (Treatment Period 3)

,,
Interventionng/mL (Geometric Mean)
Metabolite 1Metabolite 2
Padsevonil (Period 1) (PK-PPS)232.3118.6
Padsevonil (Period 2) (PK-PPS)258.3113.3
Padsevonil and Erythromycin (Period 3b) (PK-PPS)310.3101.8

[back to top]

Maximum Observed Plasma Concentration (Cmax) of Padsevonil Metabolites (1 and 2) for Single Dose

Cmax: The maximum plasma concentration of padsevonil metabolites (1 and 2) for single dose. Cmax was expressed in nanograms per milliliter (ng/mL). (NCT03480243)
Timeframe: Blood samples were taken at specific time points from pre-dose to 12 hours post first dose of Padsevonil for each Treatment Period

,,
Interventionng/mL (Geometric Mean)
Metabolite 1Metabolite 2
Padsevonil (Period 1) (PK-PPS)166.6110.5
Padsevonil (Period 2) (PK-PPS)158.794.47
Padsevonil and Erythromycin (Period 3b) (PK-PPS)189.5108.3

[back to top]

Fraction (fe) of Padsevonil and Metabolites (1, 2, and 3) Excreted Into the Urine for Single Dose

fe: The fraction of padsevonil or metabolites (1, 2, and 3) excreted into the urine for single dose. fe was expressed in percentage (%). (NCT03480243)
Timeframe: Urine samples were taken 0 to 12 hours post first dose of Padsevonil during each Treatment Period

,,
Interventionpercentage excreted (Geometric Mean)
PadsevonilMetabolite 1Metabolite 2Metabolite 3
Padsevonil (Period 1) (PK-PPS)0.039140.217010.5221.17
Padsevonil (Period 2) (PK-PPS)0.040540.24109.41919.96
Padsevonil and Erythromycin (Period 3b) (PK-PPS)0.049870.23859.76018.98

[back to top]

Fraction (fe) of Padsevonil and Metabolites (1, 2, and 3) Excreted Into the Urine for Multiple Doses

fe: The fraction of padsevonil and its metabolites (1, 2, and 3) excreted into the urine for multiple doses. fe was expressed in percentage (%). (NCT03480243)
Timeframe: Urine samples were taken 0 to 12 hours, 12 to 24 hours,and 24 to 48 hours post last PSL dose during Treatment Period 1 and 2; 0 to 12 hours, 12 to 24 hours, 24 to 48 hours, 48 to 72 hours, and 72 to 96 hours post last dose of PSL during Treatment Period 3

,,
Interventionpercentage excreted (Geometric Mean)
PadsevonilMetabolite 1Metabolite 2Metabolite 3
Padsevonil (Period 1) (PK-PPS)0.058250.604915.0251.52
Padsevonil (Period 2) (PK-PPS)0.057410.670015.0647.50
Padsevonil and Erythromycin (Period 3b) (PK-PPS)0.12740.844313.1556.69

[back to top]

Formation Clearance (CLform) of Padsevonil Metabolites (1, 2, and 3) in the Urine for Single Dose

CLform: The formation clearance of padsevonil metabolites (1, 2, and 3) in the urine for single dose. CLform was expressed in milliliters per hour (mL/hour). (NCT03480243)
Timeframe: Urine samples were taken 0 to 12 hours post first dose of Padsevonil during each Treatment Period

,,
InterventionmL/hour (Geometric Mean)
Metabolite 1Metabolite 2Metabolite 3
Padsevonil (Period 1) (PK-PPS)151.9736514820
Padsevonil (Period 2) (PK-PPS)153.4599412700
Padsevonil and Erythromycin (Period 3b) (PK-PPS)92.5937887367

[back to top]